Log in

Kardiovaskuläres und renales Risiko unter Metformin

Cardiovascular and renal risks in patients on metformin

  • Journal Club
  • Published:
Die Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Spain)

Instant access to the full article PDF.

Literatur

  1. UK Prospective Diabetes Study (UKPDS) Group. (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vojtech Pavlicek.

Ethics declarations

Interessenkonflikt

V. Pavlicek gibt die Teilnahme an „advisory boards“ an und hat Vorträge für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly gehalten.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pavlicek, V. Kardiovaskuläres und renales Risiko unter Metformin. Diabetologie 20, 630–631 (2024). https://doi.org/10.1007/s11428-024-01208-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-024-01208-7

Navigation